Biopolymer-based growth factor delivery for tissue repair: From natural concepts to engineered systems

Tissue Engineering - Part B: Reviews

Volumn 15, Issue 3, 2009, Pages 263-289

  Uebersax, Lorenz ^a   Merkle, Hans P ^a   Meinel, Lorenz ^a  

^a ETH ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ARTIFICIAL TISSUES; BIOLOGICAL PERFORMANCE; CELL SIGNALING; CELLULAR SIGNALS; CURRENT NATURE; DELIVERY SYSTEMS; ENGINEERED SYSTEMS; EXTRACELLULAR; EXTRACELLULAR MATRICES; GROWTH FACTOR; GROWTH FACTOR DELIVERY; PARACRINE; TISSUE DEFECTS; TISSUE GRAFTS; TISSUE HOMEOSTASIS; TISSUE REPAIR;

BIOACTIVITY; BIOINFORMATICS; BIOMOLECULES; BIOPOLYMERS; CELL MEMBRANES; MECHANICAL PROPERTIES; PEPTIDES; TISSUE; TISSUE ENGINEERING;

BIOMECHANICS;

ALBUMIN; ALGINIC ACID; BIOPOLYMER; BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN 2; CHITOSAN; COLLAGEN; COLLAGEN TYPE 1; FIBRIN; FIBRINOGEN; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; GELATIN; GLYCOSAMINOGLYCAN; GROWTH FACTOR; HEPARAN SULFATE; HEPARIN; HYALURONIC ACID; LATENCY ASSOCIATED PEPTIDE; OSTEOGENIC PROTEIN 1; PROTEOHEPARAN SULFATE; SCATTER FACTOR; SCLEROPROTEIN; SILK FIBROIN; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN A;

DRUG DELIVERY SYSTEM; EXTRACELLULAR MATRIX; IMPLANT; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REVIEW; TISSUE ENGINEERING; TISSUE REGENERATION; TISSUE REPAIR;

ANIMALS; BIOPOLYMERS; DRUG DELIVERY SYSTEMS; EXTRACELLULAR MATRIX; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; TISSUE ENGINEERING; WOUND HEALING;

EID: 69949145647     PISSN: 19373368     EISSN: None     Source Type: Journal    
DOI: 10.1089/ten.teb.2008.0668     Document Type: Review

References (240)

1. Rando, T.A. Stem cells, ageing and the quest for immortality. Nature 441,1080, 2006.
2. Sigal, S.H., Brill, S., Fiorino, A.S., and Reid, L.M. The liver as a stem cell and lineage system. Am J Physiol 263(2 Pt 1), G139,1992.
3. Ehrhardt, J., and Morgan, J. Regenerative capacity of skeletal muscle. Curr Opin Neurol 18, 548, 2005.
4. Conboy, I.M., Conboy, MJ., Wagers, A.J., Girma, E.R., Weissman, I.L., and Rando, T.A. Rejuvenation of aged progenitor cells by exposure to a young systemic environment. Nature 433, 760, 2005.
5. Parikh, S.N. Bone graft substitutes: past, present, future. J Postgrad Med 48,142, 2002.
6. 6. Bettin, D., Bohm, H., Clatworthy, M., Zurakowski, D., and Link, T.M. Regeneration of the donor side after autogenous fibula transplantation in 53 patients: evaluation by dual x-ray absorptiometry. Acta Orthop Scand 74, 332, 2003. (Pubitemid 36890742)
7. Rees, D.C., and Haddad, F.S. Bone transplantation. Hosp Med 64, 205, 2003.
8. 8. Kager, A.N., Marks, M., Bastrom, T., and Newton, P.O. Morbidity of iliac crest bone graft harvesting in adolescent deformity surgery. J Pediatr Orthop 26,132, 2006. (Pubitemid 44385827)
9. Honsawek, S., and Dhitiseith, D. Content of bone morphogenetic protein-4 in human demineralized bone: relationship to donor age and ability to induce new bone formation. J Med Assoc Thai 88 Suppl 4, S260, 2005.
10. Toni, R., Casa, C.D., Spaletta, G., Marchetti, G., Mazzoni, P., Bodria, M., Ravera, S., Dallatana, D., Castorina, S., Riccioli, V., Castorina, E.G., Antoci, S., Campanile, E., Scalise, G., Rossio, R., Ugolottio, G., Martorella, A., Rot, E., Sgallari, F., and Pinchera, A. The bioartificial thyroid: a biotechnological perspective in endocrine organ engineering for transplantation replacement. Acta Biomed 78 Suppl 1,129, 2007.
11. Cascone, M.G., Sim, B., and Downes, S. Blends of synthetic and natural polymers as drug delivery systems for growth hormone. Biomaterials 16, 569,1995.
12. 12. Bhattarai, N., Ramay, H.R., Gunn, J., Matsen, F.A., and Zhang, M. PEG-grafted chitosan as an injectable thermosensitive hydrogel for sustained protein release. J Control Release 103, 609, 2005. (Pubitemid 40471019)
13. 13. Viateau, V., Guillemin, G., Bousson, V., Oudina, K., Hannouche, D., Sedel, L., Logeart-Avramoglou, D., and Petite, H. Long-bone critical-size defects treated with tissueengineered grafts: a study on sheep. J Orthop Res 25, 741, 2007. (Pubitemid 46831882)
14. 14. Meinel, L., Fajardo, R., Hofmann, S., Langer, R., Chen, J., Snyder, B., Vunjak-Novakovic, G., and Kaplan, D. Silk implants for the healing of critical size bone defects. Bone 37, 688, 2005. (Pubitemid 41476392)
15. Tarla, M.R., Ramalho, F.S., Ramalho, L.N., Castro, E.S.T., Brandão, D.F., Ferreira, J., Castro, E.S.O., and Zucoloto, S. A molecular view of liver regeneration. Acta Cir Bras 21, 58, 2006.
16. Bissell, D.M. Hepatic fibrosis as wound repair: a progress report. J Gastroenterol 33, 295,1998.
17. Sykaras, N., and Opperman, L. A. Bone morphogenetic proteins (BMPs): how do they function and what can they offer the clinician? J Oral Sci 45, 57, 2003.
18. Mohan, S., and Baylink, D.J. Bone growth factors. Clin Orthop Relat Res 30, 263,1991.
19. 19. Luginbuehl, V., Wenk, E., Koch, A., Gander, B., Merkle, H.P., and Meinel, L. Insulin-like growth factor I-releasing alginate-tricalciumphosphate composites for bone regeneration. Pharm Res 22, 940, 2005. (Pubitemid 40898104)
20. 20. Kaigler, D., Cirelli, J.A., and Giannobile, W.V. Growth factor delivery for oral and periodontal tissue engineering. Expert Opin Drug Deliv 3, 647, 2006. (Pubitemid 44383492)
21. Kirker-Head, C.A. Potential applications and delivery strategies for bone morphogenetic proteins. Adv Drug Deliv Rev 43, 65, 2000.
22. Lee, S.J. Cytokine delivery and tissue engineering. Yonsei Med J 41, 704, 2000.
23. 23. Lieberman, J.R., Daluiski, A., and Einhorn, T.A. The role of growth factors in the repair of bone. Biology and clinical applications. J Bone Joint Surg Am 84-A, 1032, 2002. (Pubitemid 34907256)
24. 24. Seeherman, H., Wozney, J., and Li, R. Bone morphogenetic protein delivery systems. Spine 27(16 Suppl 1), S16, 2002. (Pubitemid 34912617)
25. 25. Seeherman, H., and Wozney, J.M. Delivery of bone morphogenetic proteins for orthopedic tissue regeneration. Cytokine Growth Factor Rev 16, 329, 2005. (Pubitemid 40910322)
26. 26. Tabata, Y. Tissue regeneration based on growth factor release. Tissue Eng 9 Suppl 1, S5, 2003. (Pubitemid 37046603)
27. Peters, M.C., Isenberg, B.C., Rowley, J.A., and Mooney, D.J. Release from alginate enhances the biological activity of vascular endothelial growth factor. J Biomater Sci Polym Ed 9,1267,1998.
28. Pawar, R., Ben-Ari, A., and Domb, A.J. Protein and peptide parenteral controlled delivery. Expert Opin Biol Ther 4, 1203, 2004.
29. 29. Bashkin, P., Doctrow, S., Klagsbrun, M., Svahn, C.M., Folkman, J., and Vlodavsky, I. Basic fibroblast growth factor binds to subendothelial extracellular matrix and is released by heparitinase and heparin-like molecules. Biochemistry 28, 1737, 1989. (Pubitemid 19072047)
30. 30. Vlodavsky, I., Korner, G., Ishai-Michaeli, R., Bashkin, P., BarShavit, R., and Fuks, Z. Extracellular matrix-resident growth factors and enzymes: possible involvement in tumor metastasis and angiogenesis. Cancer Metastasis Rev 9, 203, 1990. (Pubitemid 20380379)
31. 31. Han, B., Yang, Z., and Nimni, M. Effects of moisture and temperature on the osteoinductivity of demineralized bone matrix. J Orthop Res 23, 855, 2005. (Pubitemid 40960038)
32. 32. Bernfield, M., Gotte, M., Park, P.W., Reizes, O., Fitzgerald, M.L., Lincecum, J., and Zako, M. Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem 68, 729, 1999. (Pubitemid 29449208)
33. 33. Klagsbrun, M., and Baird, A. A dual receptor system is required for basic fibroblast growth factor activity. Cell 67, 229, 1991. (Pubitemid 121001439)
34. 34. Goger, B., Halden, Y., Rek, A., Mosl, R., Pye, D., Gallagher, J., and Kungl, A.J. Different affinities of glycosaminoglycan oligosaccharides for monomeric and dimeric interleukin-8: a model for chemokine regulation at inflammatory sites. Biochemistry 41,1640,2002. (Pubitemid 34112754)
35. 35. Bernfield, M., Hinkes, M.T., and Gallo, R.L. Developmental expression of the syndecans: possible function and regulation. Dev Suppl 1993:205. (Pubitemid 24139761)
36. Marie, J., Abderrahim, L., Debiais, F., and Lemonnier, J. Fibroblast growth factors and osteogenesis. In: Canalis, E., ed. Skeletal Growth Factors, volume 1. Philadelphia: Lipponcott Williams & Wilkins, 2000, pp. 179-196.
37. 37. Yayon, A., Klagsbrun, M., Esko, J.D., Leder, P., and Ornitz, D.M. Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell 64, 841,1991. (Pubitemid 121001170)
38. Iozzo, R.V. Basement membrane proteoglycans: from cellar to ceiling. Nat Rev Mol Cell Biol 6, 646, 2005.
39. Whitelock, J.M., Melrose, J., and Iozzo, R.V. Diverse cell signaling events modulated by perlecan. Biochemistry 47, 11174, 2008.
40. Lander, A.D., and Selleck, S.B. The elusive functions of proteoglycans: in vivo Veritas. J Cell Biol 148, 227, 2000.
41. Sanderson, R.D., and Yang, Y. Syndecan-1: a dynamic regulator of the myeloma microenvironment. Clin Exp Metastasis 25, 149, 2008.
42. 42. Schonherr, E., and Hausser, H.J. Extracellular matrix and cytokines: a functional unit. Dev Immunol 7, 89, 2000. (Pubitemid 30821842)
43. Vlodavsky, I., Bar-Shavit, R., Ishai-Michaeli, R., Bashkin, P., and Fuks, Z. Extracellular sequestration and release of fibroblast growth factor: a regulatory mechanism? Trends Biochem Sci 16, 268,1991.
44. 44. Takada, T., Katagiri, T., Ifuku, M., Morimura, N., Kobayashi, M., Hasegawa, K., Ogamo, A., and Kamijo, R. Sulfated polysaccharides enhance the biological activities of bone morphogenetic proteins. J Biol Chem 278, 43229, 2003. (Pubitemid 37345942)
45. 45. Molteni, A., Modrowski, D., Hott, M., and Marie, P.J. Alterations of matrix- and cell-associated proteoglycans inhibit osteogenesis and growth response to fibroblast growth factor-2 in cultured rat mandibular condyle and calvaria. Cell Tissue Res 295, 523,1999. (Pubitemid 29106244)
46. 46. Zcharia, E., Philp, D., Edovitsky, E., Aingorn, H., Metzger, S., Kleinman, H.K., Vlodavsky, I., and Elkin, M. Heparanase regulates murine hair growth. Am J Pathol 166, 999, 2005. (Pubitemid 40524425)
47. 47. Kinsella, M.G., Irvin, C., Reidy, M.A., and Wight, T.N. Removal of heparan sulfate by heparinase treatment inhibits FGF-2-dependent smooth muscle cell proliferation in injured rat carotid arteries. Atherosclerosis 175, 51, 2004. (Pubitemid 38746909)
48. Smith, S.M., West, L.A., Govindraj, P., Zhang, X., Ornitz, D.M., and Hassell, J.R. Heparan and chondroitin sulfate on growth plate perlecan mediate binding and delivery of FGF-2 to FGF receptors. Matrix Biol 25, 232, 2006.
49. 49. Vincent, T.L., McLean, C.J., Full, L.E., Peston, D., and Saklatvala, J. FGF-2 is bound to perlecan in the pericellular matrix of articular cartilage, where it acts as a chondrocyte mechanotransducer. Osteoarthritis Cartilage 15, 752, 2007. (Pubitemid 46888165)
50. 50. Kasayama, S., Sumitani, S., Tanaka, A., Yamanishi, H., Nakamura, N., Matsumoto, K., and Sato, B. Heparin inhibits autocrine stimulation but not fibroblast growth factor stimulation of cell proliferation of androgen-responsive Shionogi carcinoma 115. J Cell Physiol 148, 260,1991. (Pubitemid 21910149)
51. Tanaka, H. [FGF: genes, structure, biosynthesis and function]. Nippon Rinsho 63 Suppl 10, 475, 2005.
52. 52. Vlodavsky, L, Friedmann, Y., Elkin, M., Aingorn, H., Atzmon, R., Ishai-Michaeli, R., Bitan, M., Pappo, O., Peretz, T., Michal, I., Spector, L., and Pecker, I. Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis. Nat Med 5, 793,1999. (Pubitemid 29318614)
53. 53. Ai, X., Do, A.T., Lozynska, O., Kusche-Gullberg, M., Lindahl, U., and Emerson, C.P., Jr. QSulfl remodels the 6-0 sulfation states of cell surface heparan sulfate proteoglycans to promote Wnt signaling. J Cell Biol 162, 341, 2003. (Pubitemid 36928846)
54. 54. Jalkanen, M., Rapraeger, A., Saunders, S., and Bernfield, M. Cell surface proteoglycan of mouse mammary epithelial cells is shed by cleavage of its matrix-binding ectodomain from its membrane-associated domain. J Cell Biol 105(6 Pt 2), 3087,1987. (Pubitemid 18043883)
55. Sanderson, R.D., Turnbull, J.E., Gallagher, J.T., and Lander, A.D. Fine structure of heparan sulfate regulates syndecan-1 function and cell behavior. J Biol Chem 269, 13100, 1994.
56. 56. Yang, Y., MacLeod, V., Dai, Y., Khotskaya-Sample, Y., Shriver, Z., Venkataraman, G., Sasisekharan, R., Naggi, A., Torri, G., Casu, B., Vlodavsky, I., Suva, L.J., Epstein, J., Yaccoby, S., Shaughnessy, J.D., Jr., Barlogie, B., and Sanderson, R.D. The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy. Blood 110, 2041, 2007. (Pubitemid 47443921)
57. 57. Yang, Y., Macleod, V., Miao, H.Q., Theus, A., Zhan, F., Shaughnessy, J.D., Jr., Sawyer, J., Li, J.P., Zcharia, E., Vlodavsky, L, and Sanderson, R.D. Heparanase enhances syndecan-1 shedding: a novel mechanism for stimulation of tumor growth and metastasis. J Biol Chem 282, 13326, 2007. (Pubitemid 47100527)
58. 58. Wu, D.Q., Kan, M.K., Sato, G.H., Okamoto, T., and Sato, J.D. Characterization and molecular cloning of a putative binding protein for heparin-binding growth factors. J Biol Chem 266, 16778, 1991. (Pubitemid 21907866)
59. Xie, B., Tassi, E., Swift, M.R., McDonnell, K., Bowden, E.T., Wang, S., Ueda, Y., Tomita, Y., Riegel, A.T., and Wellstein, A. Identification of the fibroblast growth factor (FGF)-interacting domain in a secreted FGF-binding protein by phage display. J Biol Chem 281, 1137, 2006.
60. 60. Kanematsu, A., Yamamoto, S., Ozeki, M., Noguchi, T., Kanatani, I., Ogawa, O., and Tabata, Y. Collagenous matrices as release carriers of exogenous growth factors. Biomaterials 25, 4513, 2004. (Pubitemid 38388611)
61. 61. Kanematsu, A., Marui, A., Yamamoto, S., Ozeki, M., Hirano, Y., Yamamoto, M., Ogawa, O., Komeda, M., and Tabata, Y. Type I collagen can function as a reservoir of basic fibroblast growth factor. J Control Release 99, 281, 2004. (Pubitemid 39222113)
62. 62. Kanematsu, A., Yamamoto, S., Noguchi, T., Ozeki, M., Tabata, Y., and Ogawa, O. Bladder regeneration by bladder acellular matrix combined with sustained release of exogenous growth factor. J Urol 170(4 Pt 2), 1633, 2003. (Pubitemid 37102431)
63. Weisel, J.W. Fibrinogen and fibrin. Adv Protein Chem 70, 247, 2005.
64. Zioncheck, T.F., Richardson, L., Liu, J., Chang, L., King, K.L., Bennett, G.L., Fugedi, P., Chamow, S.M., Schwall, R.H., and Stack, R.J. Sulfated oligosaccharides promote hepatocyte growth factor association and govern its mitogenic activity. J Biol Chem 270, 16871, 1995.
65. 65. Maccarana, M., Casu, B., and Lindahl, U. Minimal sequence in heparin/heparan sulfate required for binding of basic fibroblast growth factor. J Biol Chem 268, 23898,1993. (Pubitemid 23335364)
66. 66. Jayson, G.C., Lyon, M., Paraskeva, C., Turnbull, J.E., Deakin, J.A., and Gallagher, J.T. Heparan sulfate undergoes specific structural changes during the progression from human colon adenoma to carcinoma in vitro. J Biol Chem 273, 51, 1998. (Pubitemid 28042175)
67. 67. Sieron, A.L., Louneva, N., and Fertala, A. Site-specific interaction of bone morphogenetic protein 2 with procollagen II. Cytokine 18, 214, 2002. (Pubitemid 34777702)
68. 68. Zhu, Y., Oganesian, A., Keene, D.R., and Sandell, L.J. Type IIA procollagen containing the cysteine-rich amino propeptide is deposited in the extracellular matrix of prechondrogenic tissue and binds to TGF-betal and BMP-2. J Cell Biol 144, 1069, 1999. (Pubitemid 29238979)
69. 69. Yang, W., Gomes, R.R., Brown, A.J., Burdett, A.R., Alicknavitch, M., Farach-Carson, M.C., and Carson, D.D. Chondrogenic differentiation on perlecan domain I, collagen II, and bone morphogenetic protein-2-based matrices. Tissue Eng 12, 2009, 2006. (Pubitemid 44162858)
70. Paralkar, V.M., Weeks, B.S., Yu, Y.M., Kleinman, H.K., and Reddi, A.H. Recombinant human bone morphogenetic protein 2B stimulates PC12 cell differentiation: potentiation and binding to type IV collagen. J Cell Biol 119, 1721, 1992.
71. Reddi, A.H. Morphogenetic messages are in the extracellular matrix: biotechnology from bench to bedside. Biochem Soc Trans 28, 345, 2000.
72. Ruhrberg, C., Gerhardt, H., Golding, M., Watson, R., Ioannidou, S., Fujisawa, H., Betsholtz, C., and Shima, D.T. Spatially restricted patterning cues provided by heparinbinding VEGF-A control blood vessel branching morphogenesis. Genes Dev 16, 2684, 2002.
73. Goerges, A.L., and Nugent, M.A. pH regulates vascular endothelial growth factor binding to fibronectin: a mechanism for control of extracellular matrix storage and release. J Biol Chem 279, 2307, 2004.
74. Annes, J.P., Munger, J.S., and Rifkin, D.B. Making sense of latent TGFbeta activation. J Cell Sci 116(Pt 2), 217, 2003.
75. 75. Ge, G., and Greenspan, D.S. BMPl controls TGFbetal activation via cleavage of latent TGFbeta-binding protein. J Cell Biol 175, 111, 2006. (Pubitemid 44537203)
76. 76. Dallas, S.L., Sivakumar, P., Jones, C.J., Chen, Q., Peters, D.M., Mosher, D.F., Humphries, M.J., and Kielty, C.M. Fibronectin regulates latent transforming growth factor-beta (TGF beta) by controlling matrix assembly of latent TGF beta-binding protein-1. J Biol Chem 280, 18871, 2005. (Pubitemid 41379589)
77. Dallas, S.L., Rosser, J.L., Mundy, G.R., and Bonewald, L.F. Proteolysis of latent transforming growth factor-beta (TGFbeta)-binding protein-1 by osteoclasts. A cellular mechanism for release of TGF-beta from bone matrix. J Biol Chem 277, 21352, 2002.
78. Gregory, K.E., Ono, R.N., Charbonneau, N.L., Kuo, C.L., Keene, D.R., Bachinger, H.P., and Sakai, L.Y. The prodomain of BMP-7 targets the BMP-7 complex to the extracellular matrix. J Biol Chem 280, 27970, 2005.
79. 79. Zhang, D., Ferguson, C.M., O'Keefe, R.J., Puzas, J.E., Rosier, R.N., and Reynolds, P.R. A role for the BMP antagonist chordin in endochondral ossification. J Bone Miner Res 17, 293, 2002. (Pubitemid 34087662)
80. Clemmons, D.R. Role of insulin-like growth factor binding proteins in controlling IGF actions. Mol Cell Endocrinol 140, 19, 1998.
81. 81. Palka, J., Banikowski, E., and Jaworski, S. An accumulation of IGF-I and IGF-binding proteins in human umbilical cord. Mol Cell Biochem 206, 133, 2000. (Pubitemid 30246515)
82. 82. Bankowski, E., Palka, J., and Jaworski, S. Pre-eclampsiainduced alterations in IGF-I of human umbilical cord. Eur J Clin Invest 30, 389, 2000. (Pubitemid 30251396)
83. 83. Arai, T., Arai, A., Busby, W.H., Jr., and Gemmons, D.R. Glycosaminoglycans inhibit degradation of insulin-like growth factor-binding protein-5. Endocrinology 135, 2358, 1994. (Pubitemid 24377388)
84. 84. Kuang, Z., Yao, S., Keizer, D.W., Wang, C.C, Bach, L.A., Forbes, B.E., Wallace, J.C., and Norton, R.S. Structure, dynamics and heparin binding of the C-terminal domain of insulin-like growth factor-binding protein-2 (IGFBP-2). J Mol Biol 364, 690, 2006. (Pubitemid 44755318)
85. 85. Milne, M., Quail, J.M., Rosen, C.J., and Baran, D.T. Insulinlike growth factor binding proteins in femoral and vertebral bone marrow stromal cells: expression and regulation by thyroid hormone and dexamethasone. J Cell Biochem 81, 229, 2001. (Pubitemid 32298255)
86. 86. Conover, C.A., and Khosla, S. Role of extracellular matrix in insulin-like growth factor (IGF) binding protein-2 regulation of IGF-II action in normal human osteoblasts. Growth Horm IGF Res 13, 328, 2003. (Pubitemid 37493323)
87. Martin, J.A., Miller, B.A., Scherb, M.B., Lembke, L.A., and Buckwalter, J.A. Co-localization of insulin-like growth factor binding protein 3 and fibronectin in human articular cartilage. Osteoarthritis Cartilage 10, 556, 2002.
88. 88. Arai, T., Parker, A., Busby, W., Jr., and Clemmons, D.R. Heparin, heparan sulfate, and dermatan sulfate regulate formation of the insulin-like growth factor-I and insulinlike growth factor-binding protein complexes. J Biol Chem 269, 20388, 1994. (Pubitemid 24260439)
89. Nam, T.J., Busby, W.H., Jr., and Clemmons, D.R. Human fibroblasts secrete a serine protease that cleaves insulin-like growth factor-binding protein-5. Endocrinology 135,1385, 1994.
90. Casper, C.L., Yamaguchi, N., Kiick, K.L., and Rabolt, J.F. Functionalizing electrospun fibers with biologically relevant macromolecules. Biomacromolecules 6,1998, 2005.
91. 91. Morin, R., Kaplan, D., and Perez-Ramirez, B. Bone morphogenetic protein-2 binds as multilayers to a collagen delivery matrix: an equilibrium thermodynamic analysis. Biomacromolecules 7,131, 2006. (Pubitemid 43154487)
92. Chourasia, M.K., and Jain, S.K. Polysaccharides for colon targeted drug delivery. Drug Deliv 11, 129, 2004.
93. Bjork, I., and Lindahl, U. Mechanism of the anticoagulant action of heparin. Mol Cell Biochem 48,161,1982.
94. Linhardt, R.J., and Gunay, N.S. Production and chemical processing of low molecular weight heparins. Semin Thromb Hemost 25 Suppl 3, 5,1999.
95. DeBlois, C., Cote, M.F., and Doillon, C.J. Heparin-fibroblast growth factor-fibrin complex: in vitro and in vivo applications to collagen-based materials. Biomaterials 15, 665, 1994.
96. Sakiyama-Elbert, S.E., and Hubbell, J.A. Development of fibrin derivatives for controlled release of heparin-binding growth factors. J Control Release 65, 389, 2000.
97. Zamora, P.O., Tsang, R., Pena, L.A., Osaki, S., and Som, P. Local delivery of basic fibroblast growth factor (bFGF) using adsorbed silyl-heparin, benzyl-bis(dimethylsilylmethyl) oxycarbamoyl-heparin. Bioconjug Chem 13, 920, 2002.
98. 98. Steffens, G.C., Yao, C., Prevel, P., Markowicz, M., Schenck, P., Noah, E.M., and Pallua, N. Modulation of angiogenic potential of collagen matrices by covalent incorporation of heparin and loading with vascular endothelial growth factor. Tissue Eng 10, 1502, 2004. (Pubitemid 39557853)
99. Benoit, D.S., and Anseth, K.S. Heparin functionalized PEG gels that modulate protein adsorption for hMSC adhesion and differentiation. Acta Biomater 1, 461, 2005.
100. Lee, A.C., Yu, V.M., Lowe, J.B., 3rd, Brenner, M.J., Hunter, D.A., Mackinnon, S.E., and Sakiyama-Elbert, S.E. Controlled release of nerve growth factor enhances sciatic nerve regeneration. Exp Neurol 184, 295, 2003.
101. Sakiyama-Elbert, S.E., and Hubbell, J.A. Controlled release of nerve growth factor from a heparin-containing fibrinbased cell ingrowth matrix. J Control Release 69,149, 2000.
102. 102. Saari, H., Konttinen, Y.T., Friman, C., and Sorsa, T. Differential effects of reactive oxygen species on native synovial fluid and purified human umbilical cord hyaluronate. Inflammation 17, 403,1993. (Pubitemid 23217566)
103. Paulsson, M., Morgelin, M., Wiedemann, H., BeardmoreGray, M., Dunham, D., Hardingham, T., Heinegard, D., Timpl, R., and Engel, J. Extended and globular protein domains in cartilage proteoglycans. Biochem J 245, 763, 1987.
104. Vercruysse, K.P., and Prestwich, G.D. Hyaluronate derivatives in drug delivery. Crit Rev Ther Drug Carrier Syst 15, 513,1998.
105. Suh, K.Y., Yang, J.M., Khademhosseini, A., Berry, D., Tran, T.N., Park, H., and Langer, R. Characterization of chemisorbed hyaluronic acid directly immobilized on solid substrates. J Biomed Mater Res B Appl Biomater 72, 292, 2005.
106. 106. Hahn, S.K., Jelacic, S., Maier, R.V., Stayton, P.S., and Hoffman, A. S. Anti-inflammatory drug delivery from hyaluronic acid hydrogels. J Biomater Sci Polym Ed 15, 1111, 2004. (Pubitemid 39317376)
107. Kim, H.D., and Valentini, R.F. Retention and activity of BMP-2 in hyaluronic acid-based scaffolds in vitro. J Biomed Mater Res 59, 573, 2002.
108. Kim, S.J., Hahn, S.K., Kim, M.J., Kim, D.H., and Lee, Y.P. Development of a novel sustained release formulation of recombinant human growth hormone using sodium hyaluronate microparticles. J Control Release 104, 323, 2005.
109. Locci, P., Marinucci, L., Lilli, C., Martinese, D., and Becchetti, E. Transforming growth factor beta 1-hyaluronic acid interaction. Cell Tissue Res 281, 317,1995.
110. 110. Segura, T., Chung, P.H., and Shea, L.D. DNA delivery from hyaluronic acid-collagen hydrogels via a substratemediated approach. Biomaterials 26, 1575, 2005. (Pubitemid 39441389)
111. Jork, A., Thurmer, F., Cramer, H., Zimmermann, G., Gessner, P., Hamel, K., Hofmann, G., Kuttler, B., Hahn, HJ., Josimovic-Alasevic, O., Fritsch, K.G., and Zimmermann, U. Biocompatible alginate from freshly collected Laminaria pallida for implantation. Appl Microbiol Biotechnol 53, 224, 2000.
112. Drury, J.L., Dennis, R.G., and Mooney, D.J. The tensile properties of alginate hydrogels. Biomaterials 25, 3187, 2004.
113. Tonnesen, H.H., and Karlsen, J. Alginate in drug delivery systems. Drug Dev Ind Pharm 28, 621, 2002.
114. 114. Gu, F., Amsden, B., and Neufeld, R. Sustained delivery of vascular endothelial growth factor with alginate beads. J Control Release 96, 463, 2004. (Pubitemid 38553924)
115. Lee, K.Y., Peters, M.C., and Mooney, D.J. Comparison of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in SCID mice. J Control Release 87, 49, 2003.
116. Lee, K.Y., Peters, M.C., Anderson, K.W., and Mooney, D.J. Controlled growth factor release from synthetic extracellular matrices. Nature 408, 998, 2000.
117. Lee, K.W., Yoon, J.J., Lee, J.H., Kim, S.Y., Jung, H.J., Kim, S.J., Joh, J.W., Lee, H.H., Lee, D.S., and Lee, S.K. Sustained release of vascular endothelial growth factor from calcium- induced alginate hydrogels reinforced by heparin and chitosan. Transplant Proc 36, 2464, 2004.
118. Simmons, C.A., Alsberg, E., Hsiong, S., Kim, W.J., and Mooney, D.J. Dual growth factor delivery and controlled scaffold degradation enhance in vivo bone formation by transplanted bone marrow stromal cells. Bone 35, 562, 2004.
119. Schipper, N.G., Varum, K.M., and Artursson, P. Chitosans as absorption enhancers for poorly absorbable drugs. 1: Influence of molecular weight and degree of acetylation on drug transport across human intestinal epithelial (Caco-2) cells. Pharm Res 13, 1686, 1996.
120. 120. Rinaudo, M., Milas, M., and Le Dung, P. Characterization of chitosan. Influence of ionic strength and degree of acetylation on chain expansion. Int J Biol Macromol 15, 281, 1993. (Pubitemid 23289533)
121. 121. Aggarwal, D., and Matthew, H.W. Branched chitosans: effects of branching parameters on rheological and mechanical properties. J Biomed Mater Res A 82, 201, 2007. (Pubitemid 46906507)
122. 122. Jayakumar, R., Nwe, N., Tokura, S., and Tamura, H. Sulfated chitin and chitosan as novel biomaterials. Int J Biol Macromol 40, 75, 2007. (Pubitemid 46215727)
123. Lee, Y.M., Park, Y.J., Lee, S.J., Ku, Y., Han, S.B., Klokkevold, P.R., and Chung, C.P. The bone regenerative effect of platelet-derived growth factor-BB delivered with a chitosan/tricalcium phosphate sponge carrier. J Periodontol 71, 418, 2000.
124. 124. Park, Y.J., Kim, K.H., Lee, J.Y., Ku, Y., Lee, S.J., Min, B.M., and Chung, C.P. Immobilization of bone morphogenetic protein-2 on a nanofibrous chitosan membrane for enhanced guided bone regeneration. Biotechnol Appl Biochem 43(Pt 1), 17, 2006. (Pubitemid 43059035)
125. Hsieh, C.Y., Hsieh, H.J., Liu, H.C., Wang, D.M., and Hou, L. T. Fabrication and release behavior of a novel freezegelled chitosan/gamma-PGA scaffold as a carrier for rhBMP-2. Dent Mater 22, 622, 2006.
126. 126. Lee, J.E., Kim, K.E., Kwon, I.C., Ahn, H.J., Lee, S.H., Cho, H., Kim, H.J., Seong, S.C., and Lee, M.C. Effects of the controlled-released TGF-beta 1 from chitosan microspheres on chondrocytes cultured in a collagen/chitosan/ glycosaminoglycan scaffold. Biomaterials 25, 4163, 2004. (Pubitemid 38388580)
127. 127. Fujita, M., Ishihara, M., Morimoto, Y., Simizu, M., Saito, Y., Yura, H., Matsui, T., Takase, B., Hattori, H., Kanatani, Y., Kikuchi, M., and Maehara, T. Efficacy of photocrosslinkable chitosan hydrogel containing fibroblast growth factor2 in a rabbit model of chronic myocardial infarction. J Surg Res 126, 27, 2005. (Pubitemid 40726242)
128. 128. Mizuno, K., Yamamura, K., Yano, K., Osada, T., Saeki, S., Takimoto, N., Sakurai, T., and Nimura, Y. Effect of chitosan film containing basic fibroblast growth factor on wound healing in genetically diabetic mice. J Biomed Mater Res A 64, 177, 2003. (Pubitemid 37521481)
129. 129. Ishihara, M., Fujita, M., Obara, K., Hattori, H., Nakamura, S., Nambu, M., Kiyosawa, T., Kanatani, Y., Takase, B., Kikuchi, M., and Maehara, T. Controlled releases of FGF-2 and paclitaxel from chitosan hydrogels and their subsequent effects on wound repair, angiogenesis, and tumor growth. Curr Drug Deliv 3, 351, 2006. (Pubitemid 44534046)
130. Hulmes, D.J., Miller, A., Parry, D.A., Piez, K.A., and Woodhead-Galloway, J. Analysis of the primary structure of collagen for the origins of molecular packing. J Mol Biol 79,137, 1973.
131. Helseth, D.L., Jr., and Veis, A. Collagen self-assembly in vitro. Differentiating specific telopeptide-dependent interactions using selective enzyme modification and the addition of free amino telopeptide. J Biol Chem 256, 7118,1981.
132. 132. Itoh, S., Takakuda, K., Kawabata, S., Aso, Y., Kasai, K., Itoh, H., and Shinomiya, K. Evaluation of cross-linking procedures of collagen tubes used in peripheral nerve repair. Biomaterials 23, 4475, 2002. (Pubitemid 36151599)
133. 133. Everaerts, F., Torrianni, M., Hendriks, M., and Feijen, J. Quantification of carboxyl groups in carbodiimide crosslinked collagen sponges. J Biomed Mater Res A 83, 1176, 2007. (Pubitemid 350231780)
134. 134. Hafemann, B., Ghofrani, K., Gattner, H.G., Stieve, H., and Pallua, N. Cross-linking by l-ethyl-3- (3-dimethylaminopropyl)-carbodiimide (EDC) of a collagen/elastin membrane meant to be used as a dermal substitute: effects on physical, biochemical and biological features in vitro. J Mater Sci Mater Med 12, 437, 2001. (Pubitemid 32488120)
135. Radu, F.A., Bause, M., Knabner, P., Lee, G.W., and Friess, W.C Modeling of drug release from collagen matrices. J Pharm Sci 91, 964, 2002.
136. 136. Geiger, M., Li, R.H., and Friess, W. Collagen sponges for bone regeneration with rhBMP-2. Adv Drug Deliv Rev 55, 1613, 2003. (Pubitemid 37420006)
137. Friedlaender, G.E., Perry, C.R., Cole, J.D., Cook, S.D., Cierny, G., Muschler, G.F., Zych, G.A., Calhoun, J.H., LaForte, A.J., and Yin, S. Osteogenic protein-1 (bone morphogenetic protein-7) in the treatment of tibial nonunions. J Bone Joint Surg Am 83-A Suppl 1(Pt 2), S151, 2001.
138. 138. Arnander, C., Westermark, A., Veltheim, R., DochertySkogh, A.C., Hilborn, J., and Engstrand, T. Threedimensional technology and bone morphogenetic protein in frontal bone reconstruction. J Craniofac Surg 17, 275, 2006. (Pubitemid 44317887)
139. 139. Sellers, R.S., Zhang, R., Glasson, S.S., Kim, H.D., Peluso, D., D'Augusta, D.A., Beckwith, K., and Morris, E.A. Repair of articular cartilage defects one year after treatment with recombinant human bone morphogenetic protein-2 (rhBMP-2). J Bone Joint Surg Am 82, 151, 2000. (Pubitemid 30097015)
140. 140. Okafuji, N., Shimizu, T., Watanabe, T., Kimura, A., Kurihara, S., Furusawa, K., Hasegawa, H., and Kawakami, T. Tissue reaction to poly (lactic-co-glycolic acid) copolymer membrane in rhBMP used rabbit experimental mandibular reconstruction. Eur J Med Res 11, 394, 2006. (Pubitemid 44575700)
141. McPherson, J.M. The utility of collagen-based vehicles in delivery of growth factors for hard and soft tissue wound repair. Clin Mater 9, 225, 1992.
142. Sano, A., Maeda, M., Nagahara, S., Ochiya, T., Honma, K., Itoh, H., Miyata, T., and Fujioka, K. Atelocollagen for protein and gene delivery. Adv Drug Deliv Rev 55, 1651, 2003.
143. 143. Li, H., Wang, D., Li, S., Liu, B., and Gao, L. Sustained release of BSA from a novel drug delivery matrix-bullfrog skin collagen film. Macromol Biosci 4, 454, 2004. (Pubitemid 39257170)
144. 144. Young, S., Wong, M., Tabata, Y., and Mikos, A.G. Gelatin as a delivery vehicle for the controlled release of bioactive molecules. J Control Release 109, 256, 2005. (Pubitemid 41737269)
145. 145. Yamamoto, M., Takahashi, Y., and Tabata, Y. Controlled release by biodegradable hydrogels enhances the ectopic bone formation of bone morphogenetic protein. Biomaterials 24, 4375, 2003. (Pubitemid 36960135)
146. 146. Vandelli, M. A., Romagnoli, M., Monti, A., Gozzi, M., Guerra, P., Rivasi, F., and Forni, F. Microwave-treated gelatin microspheres as drug delivery system. J Control Release 96, 67, 2004. (Pubitemid 38438490)
147. 147. Chen, F., Wu, Z., Wang, Q., Wu, H., Zhang, Y., Nie, X., and Jin, Y. Preparation and biological characteristics of recom- binant human bone morphogenetic protein-2-loaded dextran-co-gelatin hydrogel microspheres, in vitro and in vivo studies. Pharmacology 75,133, 2005. (Pubitemid 41442835)
148. Raiche, A.T., and Puleo, D.A. In vitro effects of combined and sequential delivery of two bone growth factors. Biomaterials 25, 677, 2004.
149. Cote, M.F., Laroche, G., Gagnon, E., Chevallier, P., and Doillon, C.J. Denatured collagen as support for a FGF-2 delivery system: physicochemical characterizations and in vitro release kinetics and bioactivity. Biomaterials 25, 3761, 2004.
150. Ferry, J.D. The mechanism of polymerization of fibrinogen. Proc Natl Acad Sci USA 38, 566, 1952.
151. 151. Spotnitz, W.D., and Prabhu, R. Fibrin sealant tissue adhesive-review and update. J Long Term Eff Med Implants 15, 245, 2005. (Pubitemid 40826599)
152. Park, S.H., Park, S.R., Chung, S.I., Pai, K.S., and Min, B.H. Tissue-engineered cartilage using fibrin/hyaluronan composite gel and its in vivo implantation. Artif Organs 29,838, 2005.
153. 153. Giannoni, P., and Hunziker, E.B. Release kinetics of transforming growth factor-betal from fibrin clots. Biotechnol Bioeng 83,121, 2003. (Pubitemid 36644453)
154. Pandit, A.S., Wilson, DJ., and Feldman, D.S. Fibrin scaffold as an effective vehicle for the delivery of acidic fibroblast growth factor (FGF-I). J Biomater Appl 14, 229, 2000.
155. Campbell, P.G., Miller, E.D., Fisher, G.W., Walker, L.M., and Weiss, L.E. Engineered spatial patterns of FGF-2 immobilized on fibrin direct cell organization. Biomaterials 26, 6762, 2005.
156. Ikeda, S., and Nishinari, K. Intermolecular forces in bovine serum albumin solutions exhibiting solidlike mechanical behaviors. Biomacromolecules 1, 757, 2000.
157. 157. Fine, E.G., Decosterd, I., Papaloizos, M., Zum, A.D., and Aebischer, P. GDNF and NGF released by synthetic guidance channels support sciatic nerve
158. 158. Hadlock, T.A., Sheahan, T., Cheney, M.L., Vacanti, J.P., and Sundback, C.A. Biologic activity of nerve growth factor slowly released from microspheres. J Reconstr Microsurg 19,179, 2003; discussion 185-1176 (Pubitemid 36583512)
159. 159. Meinel, L., Illi, O.E., Zapf, J., Malfanti, M., Peter Merkle, H., and Gander, B. Stabilizing insulin-like growth factor-I in poly(D,L-lactide-co- glycolide) microspheres. J Control Release 70,193, 2001. (Pubitemid 32144803)
160. 160. Donato, L., Gamier, C., Novales, B., Durand, S., and Doublier, J.L. Heat-induced gelation of bovine serum albumin/low-methoxyl pectin systems and the effect of calcium ions. Biomacromolecules 6, 374, 2005. (Pubitemid 40277036)
161. 161. Mikhailidis, D.P., Mikhailidis, A.M., and Dandona, P. Effect of human plasma proteins on stabilisation of platelet anti-aggregatory activity of prostacyclin. Ann Clin Biochem 19 (Pt 4), 241, 1982. (Pubitemid 13226598)
162. 162. El Kadi, N., Taulier, N., Le Huerou, J.Y., Gindre, M., Urbach, W., Nwigwe, I., Kahn, P.C., and Waks, M. Unfolding and refolding of bovine serum albumin at acid pH: ultrasound and structural studies. Biophys J 91, 3397, 2006. (Pubitemid 44788273)
163. Cunniff, P.M., Fossey, S.A., Auerbach, M.A., Song, J.W., Kaplan, D.L., Adams, W., Eby, R.K., Mahoney, D., Deborah, D., and Vezie, D.L. Mechanical and thermal properties of dragline silk from the spider Nephila cavipes. Polym Adv Technol 5, 401, 1994.
164. 164. Vollrath, F., Barth, P., Basedow, A., Engstrom, W., and List, H. Local tolerance to spider silks and protein polymers in vivo. In Vivo 16, 229, 2002. (Pubitemid 34884497)
165. Inoue, S., Tanaka, K., Arisaka, F., Kimura, S., Ohtomo, K., and Mizuno, S. Silk fibroin of Bombyx mori is secreted, assembling a high molecular mass elementary unit consisting of H-chain, L-chain, and P25, with a 6:6:1 molar ratio. J Biol Chem 275, 40517, 2000.
166. 166. Mita, K., Ichimura, S., and James, T.C Highly repetitive structure and its organization of the silk fibroin gene. J Mol Evol 38, 583,1994. (Pubitemid 24177291)
167. Altman, G.H., Diaz, F., Jakuba, C., Calabro, T., Horan, R. L., Chen, J., Lu, H., Richmond, J., and Kaplan, D.L. Silk-based biomaterials. Biomaterials 24, 401, 2003.
168. Lange, F. Künstliche Bänder aus Seide. Münch Med Wochenschr 17, 834,1907.
169. 169. Meinel, L., Hofmann, S., Karageorgiou, V., Kirker-Head, C., McCool, J., Gronowicz, G., Zichner, L., Langer, R., VunjakNovakovic, G., and Kaplan, D. L. The inflammatory responses to silk films in vitro and in vivo. Biomaterials 26,147, 2005. (Pubitemid 38789097)
170. Panilaitis, B., Altman, G.H., Chen, J., Jin, H.J., Karageorgiou, V., and Kaplan, D.L. Macrophage responses to silk. Biomaterials 24, 3079, 2003.
171. 171. Uebersax, L., Hagenmuller, H., Hofmann, S., Gruenblatt, E., Muller, R., Vunjaknovakovic, G., Kaplan, D.L., Merkle, H.P., and Meinel, L. Effect of scaffold design on bone morphology in vitro. Tissue Eng 12, 3417, 2006. (Pubitemid 46037165)
172. 172. Nazarov, R., Jin, H.J., and Kaplan, D.L. Porous 3-D scaffolds from regenerated silk fibroin. Biomacromolecules 5, 718, 2004. (Pubitemid 38702237)
173. Jin, H.J., Fridrikh, S.V., Rutledge, G.C, and Kaplan, D.L. Electrospinning Bombyx mori silk with poly(ethylene oxide). Biomacromolecules 3,1233, 2002.
174. Wang, Y., Kim, UJ., Blasioli, D.J., Kim, H.J., and Kaplan, D.L. In vitro cartilage tissue engineering with 3D porous aqueous-derived silk scaffolds and mesenchymal stem cells. Biomaterials 26, 7082, 2005.
175. 175. Altman, G.H., Horan, R.L., Lu, H.H., Moreau, J., Martin, I., Richmond, J.C., and Kaplan, D.L. Silk matrix for tissue engineered anterior cruciate ligaments. Biomaterials 23, 4131, 2002. (Pubitemid 34765704)
176. Meinel, L., Karageorgiou, V., Hofmann, S., Fajardo, R., Snyder, B., Li, C., Zichner, L., Langer, R., VunjakNovakovic, G., and Kaplan, D.L. Engineering bone-like tissue in vitro using human bone marrow stem cells and silk scaffolds. J Biomed Mater Res A 71, 25, 2004.
177. Meinel, L., Karageorgiou, V., Fajardo, R., Snyder, B., Shinde-Patil, V., Zichner, L., Kaplan, D., Langer, R., and Vunjak-Novakovic, G. Bone tissue engineering using human mesenchymal stem cells: effects of scaffold material and medium flow. Ann Biomed Eng 32, 112, 2004.
178. Hofmann, S., Hagenmuller, H., Koch, A.M., Muller, R., Vunjak-Novakovic, G., Kaplan, D.L., Merkle, H.P., and Meinel, L. Control of in vitro tissue-engineered bone-like structures using human mesenchymal stem cells and porous silk scaffolds. Biomaterials 28, 1152, 2007.
179. 179. Uebersax, L., Fedele, D.E., Schumacher, C., Kaplan, D.L., Merkle, H.P., Boison, D., and Meinel, L. The support of adenosine release from adenosine kinase deficient ES cells by silk substrates. Biomaterials 27, 4599, 2006. (Pubitemid 43783220)
180. Horan, R.L., Antle, K., Collette, A.L., Wang, Y., Huang, J., Moreau, J.E., Volloch, V., Kaplan, D.L., and Altman, G.H. In vitro degradation of silk fibroin. Biomaterials 26, 3385, 2005.
181. 181. Meinel, L., Hofmann, S., Karageorgiou, V., Zichner, L., Langer, R., Kaplan, D., and Vunjak-Novakovic, G. En- gineering cartilage-like tissue using human mesenchymal stem cells and silk protein scaffolds. Biotechnol Bioeng 88, 379, 2004. (Pubitemid 39524256)
182. Sofia, S., McCarthy, M.B., Gronowicz, G., and Kaplan, D.L. Functionalized silk-based biomaterials for bone formation. J Biomed Mater Res 54,139, 2001.
183. 183. Karageorgiou, V., Meinel, L., Hofmann, S., Malhotra, A., Volloch, V., and Kaplan, D. Bone morphogenetic protein-2 decorated silk fibroin films induce osteogenic differentiation of human bone marrow stromal cells. J Biomed Mater Res A 71, 528, 2004. (Pubitemid 39489907)
184. 184. Karageorgiou, V., Tomkins, M., Fajardo, R., Meinel, L., Snyder, B., Wade, K., Chen, J., Vunjak-Novakovic, G., and Kaplan, D.L. Porous silk fibroin 3-D scaffolds for delivery of bone morphogenetic protein-2 in vitro and in vivo. J Biomed Mater Res A 78, 324, 2006. (Pubitemid 44061070)
185. Hofmann, S., Wong Po Foo, C.T., Rossetti, F., Textor, M., Vunjak-Novakovic, G., Kaplan, D.L., Merkle, H.P., and Meinel, L. Silk fibroin as an organic polymer for controlled drug delivery. J Control Release 10, 111, 2006.
186. 186. Li, C., Vepari, C., Jin, H.J., Kim, H.J., and Kaplan, D.L. Electrospun silk-BMP-2 scaffolds for bone tissue engineering. Biomaterials 27, 3115, 2006. (Pubitemid 43247585)
187. Uebersax, L., Merkle, H.P., and Meinel, L. Insulin-like growth factor I releasing silk fibroin scaffolds induce chondrogenic differentiation of human mesenchymal stem cells. J Control Release 127, 12, 2008.
188. 188. Uebersax, L., Mattotti, M., Papaloizos, M., Merkle, H.P., Gander, B., and Meinel, L. Silk fibroin matrices for the controlled release of nerve growth factor (NGF). Biomaterials 28, 4449, 2007. (Pubitemid 47225114)
189. 189. Wang, X., Wenk, E., Matsumoto, A., Meinel, L., Li, C., and Kaplan, D.L. Silk microspheres for encapsulation and controlled release. J Control Release 117, 360, 2007. (Pubitemid 46216582)
190. Giusti, P., Lazzeri, L., De Petris, S., Palla, M., and Cascone, M.G. Collagen-based new bioartificial polymeric materials. Biomaterials 15, 1229, 1994.
191. 191. Prabaharan, M., and Mano, J.F. Stimuli-responsive hydrogels based on polysaccharides incorporated with thermoresponsive polymers as novel biomaterials. Macromol Biosci 6, 991, 2006. (Pubitemid 46032936)
192. 192. Huang, X., and Lowe, T.L. Biodegradable thermoresponsive hydrogels for aqueous encapsulation and controlled release of hydrophilic model drugs. Biomacromolecules 6, 2131, 2005. (Pubitemid 41052209)
193. 193. Kato, M., Wang, H., Kainulainen, V., Fitzgerald, M.L., Ledbetter, S., Ornitz, D.M., and Bemfield, M. Physiological degradation converts the soluble syndecan-1 ectodomain from an inhibitor to a potent activator of FGF-2. Nat Med 4, 691, 1998. (Pubitemid 28274669)
194. Whitelock, J.M., Murdoch, A.D., Iozzo, R.V., and Underwood, P.A. The degradation of human endothelial cellderived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin, and heparanases. J Biol Chem 271, 10079, 1996.
195. Murphy, A.R., St. John, P., and Kaplan, D.L. Modification of silk fibroin using diazonium coupling chemistry and the effects on hMSC proliferation and differentiation. Biomaterials 29, 2829, 2008.
196. Werz, D.B., and Seeberger, P.H. Carbohydrates as the next frontier in pharmaceutical research. Chemistry 11, 3194, 2005.
197. 197. Freeman, C., Liu, L., Banwell, M.G., Brown, K.J., Bezos, A., Ferro, V., and Parish, C.R. Use of sulfated linked cyclitols as heparan sulfate mimetics to probe the heparin/heparan sulfate binding specificity of proteins. J Biol Chem 280, 8842, 2005. (Pubitemid 40409573)
198. 198. Jemth, P., Smeds, E., Do, A.T., Habuchi, H., Kimata, K., Lindahl, U., and Kusche-Gullberg, M. Oligosaccharide library-based assessment of heparan sulfate 6-O-sulfotransferase substrate specificity. J Biol Chem 278, 24371, 2003. (Pubitemid 37548588)
199. 199. Ashikari-Hada, S., Habuchi, H., Kariya, Y., Itoh, N., Reddi, A.H., and Kimata, K. Characterization of growth factorbinding structures in heparin/heparan sulfate using an octasaccharide library. J Biol Chem 279, 12346, 2004. (Pubitemid 38445801)
200. de Paz, J.L., Noti, C., and Seeberger, P.H. Microarrays of synthetic heparin oligosaccharides. J Am Chem Soc 128, 2766, 2006.
201. 201. Gengrinovitch, S., Berman, B., David, G., Witte, L., Neufeld, G., and Ron, D. Glypican-1 is a VEGF165 binding proteoglycan that acts as an extracellular chaperone for VEGF165. J Biol Chem 274, 10816, 1999. (Pubitemid 129528283)
202. 202. Koide, T. Triple helical collagen-like peptides: engineering and applications in matrix biology. Connect Tissue Res 46, 131, 2005. (Pubitemid 41283146)
203. Woolfson, D.N., and Ryadnov, M.G. Peptide-based fibrous biomaterials: some things old, new and borrowed. Curr Opin Chem Biol 10, 559, 2006.
204. 204. Holmes, T.C., de Lacalle, S., Su, X., Liu, G., Rich, A., and Zhang, S. Extensive neurite outgrowth and active synapse formation on self-assembling peptide scaffolds. Proc Natl Acad Sci USA 97, 6728, 2000. (Pubitemid 30412782)
205. Gentilucci, L., Tolomelli, A., and Squassabia, F. Peptides and peptidomimetics in medicine, surgery and biotechnology. Curr Med Chem 13, 2449, 2006.
206. Sidman, K.R., Steber, W.D., Schwope, A.D., and Schnaper, G.R. Controlled release of macromolecules and pharmaceuticals from synthetic polypeptides based on glutamic acid. Biopolymers 22, 547, 1983.
207. 207. Bourke, S.L., and Kohn, J. Polymers derived from the amino acid L-tyrosine: polycarbonates, polyarylates and copolymers with poly(ethylene glycol). Adv Drug Deliv Rev 55, 447, 2003. (Pubitemid 36423299)
208. 208. Schachter, D.M., and Kohn, J. A synthetic polymer matrix for the delayed or pulsatile release of water-soluble peptides. J Control Release 78, 143, 2002. (Pubitemid 34081860)
209. Maynard, H.D., and Hubbell, J.A. Discovery of a sulfated tetrapeptide that binds to vascular endothelial growth factor. Acta Biomater 1, 451, 2005.
210. 210. Megeed, Z., Cappello, J., and Ghandehari, H. Genetically engineered silk-elastinlike protein polymers for controlled drug delivery. Adv Drug Deliv Rev 54, 1075, 2002. (Pubitemid 35217757)
211. Hart, D.S., and Gehrke, S.H. Thermally associating polypeptides designed for drug delivery produced by genetically engineered cells. J Pharm Sci 96, 484, 2007.
212. 212. Olsen, D., Yang, C., Bodo, M., Chang, R., Leigh, S., Baez, J., Carmichael, D., Perala, M., Hamalainen, E.R., Jarvinen, M., and Polárek, J. Recombinant collagen and gelatin for drug delivery. Adv Drug Deliv Rev 55, 1547, 2003. (Pubitemid 37412593)
213. 213. Sutter, M., Siepmann, J., Hennink, W.E., and Jiskoot, W. Recombinant gelatin hydrogels for the sustained release of proteins. J Control Release 119, 301, 2007. (Pubitemid 46783840)
214. Heslot, H. Artificial fibrous proteins: a review. Biochimie 80, 19, 1998.
215. 215. Wong Po Foo, C., and Kaplan, D.L. Genetic engineering of fibrous proteins: spider dragline silk and collagen. Adv Drug Deliv Rev 54,1131, 2002. (Pubitemid 35264524)
216. Wurm, F.M. Human therapeutic proteins from silkworms. Nat Biotechnol 21, 34, 2003.
217. Griffiths, B., and Wurm, F.M. Mammalian cell culture. In: Meyers, R.A., ed. Encyclopedia of Physical Sciences and Technology. New York: Academic Press, volume 9, edition 3. 2002, pp. 31-47.
218. 218. Tomita, M., Munetsuna, H., Sato, T., Adachi, T., Hino, R., Hayashi, M., Shimizu, K., Nakamura, N., Tamura, T., and Yoshizato, K. Transgenic silkworms produce recombinant human type III procollagen in cocoons. Nat Biotechnol 21, 52, 2003. (Pubitemid 36055827)
219. Adachi, T., Tomita, M., Shimizu, K., Ogawa, S., and Yoshizato, K. Generation of hybrid transgenic silkworms that express Bombyx mori prolyl-hydroxylase alpha-subunits and human collagens in posterior silk glands: production of cocoons that contained collagens with hydroxylated proline residues. J Biotechnol 126, 205, 2006.
220. Mori, H., and Tsukada, M. New silk protein: modification of silk protein by gene engineering for production of biomaterials. J Biotechnol 74, 95, 2000.
221. Yamamoto, M., Yamao, M., Nishiyama, H., Sugihara, S., Nagaoka, S., Tomita, M., Yoshizato, K., Tamura, T., and Mori, H. New and highly efficient method for silkworm transgenesis using Autographa californica nucleopolyhedrovirus and piggyBac transposable elements. Biotechnol Bioeng 88, 849, 2004.
222. Yang, M., Tanaka, C., Yamauchi, K., Ohgo, K., Kurokawa, M., and Asakura, T. Silk like materials constructed from sequences of Bombyx mori silk fibroin, fibronectin, and elastin. J Biomed Mater Res A 84, 353, 2008.
223. 223. Serieller, J., and Conrad, U. Plant-based material, protein and biodegradable plastic. Curr Opin Plant Biol 8, 188, 2005. (Pubitemid 40323549)
224. 224. Serieller, J., Henggeler, D., Viviani, A., and Conrad, U. Purification of spider silk-elastin from transgenic plants and application for human chondrocyte proliferation. Transgenic Res 13, 51, 2004. (Pubitemid 38335389)
225. Li, M., Tu, G., Huang, Z., and Huang, X. [Study on the conditions of high density fermentation for the engineering bacterial strain with RGD spider silk protein gene]. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi 22,1206, 2005.
226. 226. Yao, J., Yanagisawa, S., and Asakura, T. Design, expression and characterization of collagen-like proteins based on the cell adhesive and crosslinking sequences derived from native collagens. J Biochem (Tokyo) 136, 643, 2004. (Pubitemid 40364187)
227. 227. Cappello, J., Crissman, J., Dorman, M., Mikolajczak, M., Textor, G., Marquet, M., and Ferrari, F. Genetic engineering of structural protein polymers. Biotechnol Prog 6, 198, 1990. (Pubitemid 20710575)
228. Megeed, Z., Haider, M., Li, D., O'Malley, B.W., Jr., Cappello, J., and Ghandehari, H. In vitro and in vivo evaluation of recombinant silk-elastinlike hydrogels for cancer gene therapy. J Control Release 94, 433, 2004.
229. 229. Haider, M., Leung, V., Ferrari, F., Crissman, J., Powell, J., Cappello, J., and Ghandehari, H. Molecular engineering of silk-elastinlike polymers for matrix-mediated gene delivery: biosynthesis and characterization. Mol Pharm 2, 139, 2005. (Pubitemid 41295361)
230. 230. Davis, M.E., Hsieh, P.C., Takahashi, T., Song, Q., Zhang, S., Kamm, R.D., Grodzinsky, A.J., Anversa, P., and Lee, R.T. Local myocardial insulin-like growth factor 1 (IGF-I) delivery with biotinylated peptide nanofibers improves cell therapy for myocardial infarction. Proc Natl Acad Sci USA 103, 8155, 2006. (Pubitemid 43801068)
231. 231. Patel, S., Kurpinski, K., Quigley, R., Gao, H., Hsiao, B.S., Poo, M.M., and Li, S. Bioactive nanofibers: synergistic ef- fects of nanotopography and chemical signaling on cell guidance. Nano Lett 7, 2122, 2007. (Pubitemid 47197602)
232. Geer, DJ., Swartz, D.D., and Andreadis, S.T. Biomimetic delivery of keratinocyte growth factor upon cellular demand for accelerated wound healing in vitro and in vivo. Am J Pathol 167, 1575, 2005.
233. 233. Vessillier, S., Adams, G., and Chemajovsky, Y. Latent cytokines: development of novel cleavage sites and kinetic analysis of their differential sensitivity to MMP-I and MMP-3. Protein Eng Des Sel 17, 829, 2004. (Pubitemid 40392906)
234. 234. Ehrbar, M., Metters, A., Zammaretti, P., Hubbell, J.A., and Zisch, A.H. Endothelial cell proliferation and progenitor maturation by fibrin-bound VEGF variants with differential susceptibilities to local cellular activity. J Control Release 101, 93, 2005. (Pubitemid 39600975)
235. 235. Chen, B., Lin, H., Zhao, Y., Wang, B., Zhao, Y., Liu, Y., Liu, Z., and Dai, J. Activation of demineralized bone matrix by genetically engineered human bone morphogenetic protein-2 with a collagen binding domain derived from von Willebrand factor propolypeptide. J Biomed Mater Res A 80, 428, 2007. (Pubitemid 46122677)
236. 236. Yang, V.C., Naik, S.S., Song, H., Dombkowski, A.A., Crippen, G., and Liang, J.F. Construction and characterization of a t-PA mutant for use in ATTEMPTS: a drug delivery system for achieving targeted thrombolysis. J Control Release 110, 164, 2005. (Pubitemid 41713940)
237. 237. Park, Y.J., Liang, J.F., Song, H., Li, Y.T., Naik, S., and Yang, V.C. ATTEMPTS: a heparin/protamine-based triggered release system for the delivery of enzyme drugs without associated side-effects. Adv Drug Deliv Rev 55, 251, 2003. (Pubitemid 36138815)
238. 238. Liang, J.F., Park, Y.J., Song, H., Li, Y.T., and Yang, V.C. ATTEMPTS: a heparin/protamine-based prodrug approach for delivery of thrombolytic drugs. J Control Release 72,145, 2001. (Pubitemid 32522352)
239. Liang, J.F., Li, Y.T., and Yang, V.C. A novel approach for delivery of enzyme drugs: preliminary demonstration of feasibility and utility in vitro. Int J Pharm 202, 11, 2000.
240. 240. Ramirez, F., and Rifkin, D.B. Cell signaling events: a view from the matrix. Matrix Biol 22, 101, 2003. (Pubitemid 36627468)